Haruko Daga

2.9k citations

92 papers · 911 · h-index 16

Impact in

Oncology top 5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 75
- Lung Cancer Treatments and Mutations 62
- Lung Cancer Diagnosis and Treatment 25
- Gastric Cancer Management and Outcomes 10
Oncology 66
- Lung Cancer Research Studies 32
- Cancer Immunotherapy and Biomarkers 15
- Colorectal Cancer Treatments and Studies 15
- Cancer Treatment and Pharmacology 9

Co-authors: Nobuyuki Yamamoto (29 shared papers)Kazuhiko Nakagawa (31 shared papers)Isamu Okamoto (23 shared papers)Shunichi Sugawara (18 shared papers)Takashi Seto (17 shared papers)Kōichi Goto (20 shared papers)Toshiaki Takahashi (16 shared papers)Kazumi Nishino (14 shared papers)
Journals: Journal of Clinical Oncology (23 papers)Annals of Oncology (10 papers)Journal of Thoracic Oncology (7 papers)Investigational New Drugs (4 papers)Clinical Lung Cancer (4 papers)
Partner nations: Japan United States South Korea

In The Last Decade

Haruko Daga

82 papers receiving 897 citations

Peers

Countries citing papers authored by Haruko Daga

Since Specialization

Citations

This map shows the geographic impact of Haruko Daga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruko Daga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruko Daga more than expected).

Fields of papers citing papers by Haruko Daga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruko Daga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruko Daga. The network helps show where Haruko Daga may publish in the future.

Co-authors

The 25 scholars most cited alongside Haruko Daga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Haruko Daga Line = papers co-authored together Haruko Daga links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA Clinical Chemistry ·Junji Uchida, Kikuya Kato, Yoji Kukita, Toru Kumagai, Kazumi Nishino, Haruko Daga, Izumi Nagatomo, Takako Inoue, Madoka Kimura, Shigeyuki Oba, Yuri Ito, Koji Takeda, Fumio Imamura	2015	91
2	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, Katsuo Yoshiya, Toshiaki Takahashi, Tsuyoshi Ueno, Kōichi Goto, Haruko Daga, Norihiko Ikeda, Kenji Sugio, Takashi Seto, Shinichi Toyooka, Hiroshi Date, Tetsuya Mitsudomi, Isamu Okamoto, Kohei Yokoi, Hideo Saka, Hiroaki Okamoto, Yuichi Takiguchi, Masahiro Tsuboi	2020	70
3	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial The Lancet Oncology ·Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, Haruko Daga, Kōichi Goto, Hideo Saka, Shunichi Sugawara, Toshiaki Takahashi, Soichiro Yokota, Hiroyasu Kaneda, Tomoya Kawaguchi, Seisuke Nagase, Tetsuya Oguri, Yasuo Iwamoto, Takashi Nishimura, Yoshihiro Hattori, Kazuhiko Nakagawa, Yoichi Nakanishi, Nobuyuki Yamamoto	2015	65
4	Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations European Journal of Cancer ·Eiji Iwama, Yoshitaka Zenke, Shunichi Sugawara, Haruko Daga, Masahiro Morise, Noriko Yanagitani, Tomohiro Sakamoto, Haruyasu Murakami, Junji Kishimoto, Shingo Matsumoto, Yoichi Nakanishi, Kōichi Goto, Isamu Okamoto	2021	52
5	A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib Japanese Journal of Clinical Oncology ·Shiro Kimbara, Kazuya Takeda, Hiroko Fukushima, Toru Inoue, Hideto Okada, Yuji Shibata, Utae Katsushima, Asuka Tsuya, S. Tokunaga, Haruko Daga, Tatsusada Okuno	2014	50
6	Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed Journal of Thoracic Oncology ·Naruo Yoshimura, Kyoichi Okishio, Shigeki Mitsuoka, Tatsuo Kimura, Tomoya Kawaguchi, Masaji Kobayashi, Tomonori Hirashima, Haruko Daga, Koji Takeda, Kazuto Hirata, Shinzoh Kudoh	2012	42
7	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) Journal for ImmunoTherapy of Cancer ·Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa	2022	38
8	Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer JAMA Oncology ·Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Takayasu Kurata, Shunichi Sugawara, Yoshimasa Shiraishi, Shunsuke Teraoka, Koichi Azuma, Haruko Daga, Masafumi Yamaguchi, Takeshi Kodaira, Miyako Satouchi, Mototsugu Shimokawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa, (unknown)	2023	33
9	Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial Cancer ·Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, Haruyasu Murakami, Haruhiro Saito, Akihito Kubo, Toshiyuki Sawa, Eiji Miyahara, Naoyuki Nogami, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto	2016	33
10	Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206 Journal of Clinical Oncology ·Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, Masashi Wakabayashi, Genichiro Ishii, Kazuo Nakagawa, Haruko Daga, Hiroshi Tanaka, Haruhiro Saito, Keiju Aokage, Toshiaki Takahashi, Toshi Menju, Takashi Kasai, Ichiro Yoshino, Koichi Minato, Morihito Okada, Junko Eba, Hisao Asamura, Yuichiro Ohe, Shun-ichi Watanabe	2020	26
11	Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L Journal of Thoracic Oncology ·Hiroaki Akamatsu, Haruyasu Murakami, Hideyuki Harada, Junichi Shimizu, Hidetoshi Hayashi, Haruko Daga, Yoshikazu Hasegawa, Young Hak Kim, Terufumi Kato, Shoji Tokunaga, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa	2021	25
12	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) Journal of Clinical Oncology ·Takashi Seto, Koichi Azuma, Takeharu Yamanaka, Shunichi Sugawara, Hiroshige Yoshioka, Kazushige Wakuda, Shinji Atagi, Yasuo Iwamoto, Hidetoshi Hayashi, Isamu Okamoto, Hideo Saka, Shigeki Mitsuoka, Daichi Fujimoto, Kazumi Nishino, Atsushi Horiike, Haruko Daga, Takashi Sone, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yoichi Nakanishi	2019	25
13	Glutathione S-transferase-π gene expression and platinum drug exposure in human lung cancer Cancer Letters ·Tetsuya Oguri, Yasuhiro Fujiwara, Osamu Katoh, Haruko Daga, Nobuhisa Ishikawa, Kazunori Fujitaka, Masahiro Yamasaki, Michiya Yokozaki, Takeshi Isobe, Shinichi Ishioka, Michio Yamakido	2000	23
14	Prospective Study of Urinary and Serum Cross-Linked N-Telopeptide of Type I Collagen (NTx) for Diagnosis of Bone Metastasis in Patients With Lung Cancer Clinical Lung Cancer ·Motohiro Tamiya, Shinya Tokunaga, Hideaki Okada, Hidekazu Suzuki, Masashi Kobayashi, Shinji Sasada, Norio Okamoto, Naoko Morishita, Yuka Matsuura, N. Miyamoto, Michiyo Hattori, Koichi Taira, Haruko Daga, Koji Takeda, Tomonori Hirashima	2012	16
15	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial Investigational New Drugs ·Kazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, Hisao Imai, Motohiro Tamiya, Takaaki Tokito, Takahisa Kawamura, Hiroaki Akamatsu, Yuko Tsuboguchi, Toshiaki Takahashi, Nobuyuki Yamamoto, Keita Mori, Haruyasu Murakami	2020	15
16	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. Journal of Clinical Oncology ·Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu-Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Sarah Ng, Xin Huang, Alexander Drilon	2020	15
17	Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) Molecular Oncology ·Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Kazuto Nishio	2020	15
18	First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients ESMO Open ·Kenneth J. O’Byrne, K.H. Lee, S.-W. Kim, K. Park, Makoto Nishio, Hiroshi Sakai, Yuichiro Ohe, Tatsuro Fukuhara, Jin Hyoung Kang, Haruko Daga, Chong‐Jen Yu, Katsuyuki Hotta, Hiroshi Tanaka, Masayuki Takeda, Toshihide Yokoyama, Faith E. Nathan, J.-S. Lee	2022	14
19	Osimertinib for patients with EGFR T790M mutation-positive non–small-cell lung cancer and a poor performance status Japanese Journal of Clinical Oncology ·Kazuhisa Nakashima, Madoka Kimura, Hiroaki Akamatsu, Haruko Daga, Hisao Imai, Tetsuhiko Taira, Ryo Ko, Yasushi Hisamatsu, Kazumi Nishino, Takeya Sugimoto, Yosuke Miyashita, Toshiaki Takahashi, (unknown)	2019	14
20	A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer Medical Oncology ·Motohiro Tamiya, Akihiro Tamiya, Hiroyasu Kaneda, Kazuhiko Nakagawa, Kiyotaka Yoh, Kōichi Goto, Hiroaki Okamoto, Tsuneo Shimokawa, Tetsuya Abe, Hiroshi Tanaka, Haruko Daga, Koji Takeda, Tomonori Hirashima, Shinji Atagi	2015	12

About Haruko Daga

Haruko Daga is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 92 papers that have together received 911 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (32 papers), Lung Cancer Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (15 papers), Colorectal Cancer Treatments and Studies (15 papers), Cancer Genomics and Diagnostics (11 papers), Gastric Cancer Management and Outcomes (10 papers) and Cancer Treatment and Pharmacology (9 papers). The work is most often cited by research in Oncology (594 citations), Pulmonary and Respiratory Medicine (611 citations), Cancer Research (182 citations), Pathology and Forensic Medicine (55 citations) and Otorhinolaryngology (13 citations). Haruko Daga has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Nobuyuki Yamamoto, Kazuhiko Nakagawa, Isamu Okamoto, Shunichi Sugawara, Takashi Seto, Kōichi Goto, Toshiaki Takahashi, Kazumi Nishino, Hidetoshi Hayashi and Haruyasu Murakami. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Investigational New Drugs and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Haruko Daga

Impact in

Papers in i

In The Last Decade

Haruko Daga

Peers

Countries citing papers authored by Haruko Daga

Fields of papers citing papers by Haruko Daga

All Works

About Haruko Daga

Explore authors with similar magnitude of impact

Papers in